Dear Ladies and Gentlemen,
Dear Colleagues,

We herewith cordially invite you to the 14th Congress of the European Headache Society in Berlin.

New and exciting times are dawning, with a slew of new therapies underway: CGRP antibodies for migraine prophylaxis, lasmiditan as an alternative to triptans for acute therapy, atogepant, ubrogepant, possibly PACAP antibodies and more. That is why we chose “Head over Ache – Silver Lining Novel Treatments” for the motto of the 14th European Headache Federation Congress.

Now we, physicians, psychologists, cost bearers, politicians, and those working in health care, must make sure that the new as well as the old treatments reach the right patients in the optimal way.

We therefore invite doctors and scientists from Europe and abroad, but also our partners EFIC, EAN, WONCA, EMA, and WHO to take part in this event. The scientific committee will be co-chaired by Professor Richard Lipton, US.

We warmly welcome you to the Maritim Hotel from 3–5 July 2020 in wonderful Berlin, which is always worth a visit, especially at the beginning of summer! Together, let’s explore the future of headache treatment here in the capital of Germany. I remain in anticipation of interesting contributions and a profitable discussion,

Yours sincerely,

Zaza Katsarava
President EHF & Congress chair EHF 2020
**PROGRAMME AND TOPICS**

**New treatments**
Impact of CGRP targeted therapies in practice: Evidence from clinical trials and clinical practice
*Overview of approved and soon to be approved preventive treatments, real-world evidence on patterns of use and impact on outcomes*

**New targets**
Emphasizes the generation of mechanisms that will lead to the next generation of treatment

**Prognostic biomarkers and individualized treatment**
Identifying natural subgroups of people with migraine: Approaches to personalized medicine
*Review on the evidence that symptom profiles, comorbidity, triggers, treatment response, genetics, biomarkers and imaging can be used to identify natural subgroups of people with migraine and that those subgroups are useful in individualizing treatment and improving outcomes*

**Headache and public health**
Measuring the interictal burden of migraine, WHO perspectives

**Regulatory and reimbursement science in headache medicine**
EMA, FDA, NICE perspectives
Role of MBS as an acute treatment outcome

**Latest and greatest headache science**
Role of gylmphatic system in migraine, mechanisms of individual symptoms such as nausea, photo, phono, etc.

**Young scientific talents**
EHF – School of Advanced Studies presents its work

**EHF invites:**
EFIC – European Pain Federation
WONCA – World Organization of National Colleges Academies and Academic Associations of General Practitioners/Family Physicians
EMA – European Medicines Agency
WHO – World Health Organization
to talk about headache

**GENERAL INFORMATION**

**Venue**
Maritim Hotel Berlin
Stauffenbergstraße 26  I  10785 Berlin, Germany

**Congress Website**
www.ehf2020.com

**Scientific Committee Chairs**
Professor Zaza Katsarava
*Chief, Department of Neurology*
Evangelical Hospital Unna, Germany
*Professor of Neurology*
Medical Faculty, University of Essen, Germany

Professor Richard B. Lipton
*Director, Division of Cognitive Aging and Dementia*
*Director, Montefiore Headache Center*
Albert Einstein College of Medicine
New York, US

**Industrial Exhibition**
Interested companies are invited to request information on the sponsor and exhibition modalities from the congress organization Conventus.

**Professional Congress Organizer**
Conventus Congressmanagement & Marketing GmbH
Phone +49 3641 31 16-406
ehf2020@conventus.de  l  www.conventus.de